Breast cancer

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Retrieved on: 
Jeudi, avril 11, 2024
Breast cancer, VUS, Medical school, Patient, Oncogenomics, Laboratory, OTC, FACMG, Machine learning, Research, Health, REA, Genetic testing, Black, DSM-IV codes, Classification, Society, Cancer, Algorithm, SAN, Gene

SAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.

Key Points: 
  • The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.
  • After validating gene-specific machine learning algorithms, the impact on variant classification was analyzed in patients with breast cancer who underwent hereditary cancer genetic testing from January 2022 - May 2023.
  • Results offer reassurance that variants of uncertain significance in genetic testing results among breast cancer patients do not lead to overuse of breast surgeries, like mastectomies.
  • This study titled, "Real-World Breast Surgery Utilization among Breast Cancer Patients with Germline Variants of Uncertain Significance," examines breast surgery uptake in a large, recent sample of breast cancer patients undergoing genetic testing.

ImpediMed to Present Chronic Breast Cancer-related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Retrieved on: 
Jeudi, avril 11, 2024
FDA, Cancer, American Cancer Society, Risk, Woman, Cleveland Clinic, Lymphedema, Research, Body composition, BIS, Patient, Society, Melanoma, MBA, Quality of life, Breast cancer, Medical imaging

CARLSBAD, Calif., April 11, 2024 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024.

Key Points: 
  • CARLSBAD, Calif., April 11, 2024 /PRNewswire/ -- ImpediMed , a leader in medical technologies to clinically monitor and manage fluid and body composition, announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024.
  • "Chronic breast cancer-related lymphedema can represent a risk to patients who have undergone breast cancer treatment with meaningful impact on their quality of life," said Chirag Shah, MD, Co-Director of the Comprehensive Breast Cancer Program, Cleveland Clinic, lead author of the study, and scientific adviser to ImpediMed.
  • ImpediMed Chief Medical Officer, Steven L. Chen, MD, MBA, one of the study's authors, will present the findings at ASBrS.
  • According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Jeudi, avril 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Jeudi, avril 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

"Show Her The Money," A Groundbreaking New Documentary About The Power Of Funding Women Entrepreneurs, Has Launched A 50-City Grassroots Global Tour Sponsored By Wells Fargo

Retrieved on: 
Jeudi, avril 11, 2024
Breast cancer, Money, Wine, Glass, Wells Fargo, Woman, City, Human, Carbon, Female, Silicon, BIPOC, Emmy Awards, Knowledge, Entertainment

LOS ANGELES, April 11, 2024 /PRNewswire/ -- Following its award-winning film festival run, producer Catherine Gray announced that the documentary "Show Her The Money" has embarked on a 50-city grassroots global tour to shed light on the plight of women entrepreneurs who aren't getting their share of venture capital.

Key Points: 
  • "The stories told by the pioneering women featured throughout "Show Her The Money" demonstrate how far we've come.
  • Through an immersive 50-city grassroots global tour, we are committed to raising awareness and fostering change in the way women are funded in the entrepreneurial sphere."
  • "This film is a great opportunity to educate and inspire women, and we look forward to sharing the film with businesswomen nationwide through this grassroots global tour."
  • Jasmine Jones, inspired by her grandmother's battle with breast cancer, founded Myya, the only online direct-to-consumer, insurance billable, post-mastectomy intimates' brand.

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Retrieved on: 
Jeudi, avril 11, 2024
FDA, CDK, Paclitaxel, Progression-free survival, Survival, TSX, AB, MBC, ONC, Patient, Biomarker, SAN, Type, Breast cancer, Overalls, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, April 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).

Key Points: 
  • This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment.
  • We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • "We eagerly anticipate our discussion with the FDA to align on the design and objectives of the registrational trial for pelareorep in metastatic breast cancer, a critical step towards bringing this innovative treatment to patients.

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Retrieved on: 
Jeudi, avril 11, 2024
FDA, CDK, Paclitaxel, Progression-free survival, Survival, TSX, AB, MBC, ONC, Patient, Biomarker, SAN, Type, Breast cancer, Overalls, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, April 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).

Key Points: 
  • This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment.
  • We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • "We eagerly anticipate our discussion with the FDA to align on the design and objectives of the registrational trial for pelareorep in metastatic breast cancer, a critical step towards bringing this innovative treatment to patients.

Ferrum Health Expands AI Offerings in Partnership with Radiology Associates of Albuquerque (RAA)

Retrieved on: 
Mercredi, avril 10, 2024
CFO, Radiology, Investment, AI, Partnership, Intelligence, RAA, Patient, Health, Breast cancer, Medical imaging

ALBUQUERQUE, N.M., April 10, 2024 /PRNewswire/ -- Ferrum Health , the leading artificial intelligence platform for healthcare, is excited to announce that Gleamer's BoneView is now available to assist clinicians in the detection of bone trauma in Albuquerque, New Mexico.

Key Points: 
  • ALBUQUERQUE, N.M., April 10, 2024 /PRNewswire/ -- Ferrum Health , the leading artificial intelligence platform for healthcare, is excited to announce that Gleamer's BoneView is now available to assist clinicians in the detection of bone trauma in Albuquerque, New Mexico.
  • This represents an expansion of the Ferrum Platform at Radiology Associates of Albuquerque (RAA), which previously launched iCAD's ProFound Suite last summer, an algorithm designed to assist radiologists in detecting breast cancer.
  • "We are thrilled to partner with Radiology Associates of Albuquerque to expand their AI capabilities," said Peter Eason, CFO at Ferrum Health.
  • RAA and Ferrum Health look to continue the expansion of AI innovation through 2024 and beyond.

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Retrieved on: 
Mercredi, avril 10, 2024
Breast cancer, FDA, Patient, Cancer, Daiichi Sankyo, Lung cancer, HER2, Food, ROG, Marie Cassidy, ADC, Food and Drug Administration, AstraZeneca, CE marking, Medical imaging

ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.

Key Points: 
  • ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.
  • To determine a patient's HER2 status, pathologists evaluate, or score, the level of HER2 protein expressed in breast cancer tissue samples.
  • However, half of all patients with metastatic breast cancer express low levels of HER2 which historically classified them as HER2-negative.
  • Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases diagnosed worldwide each year.

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Retrieved on: 
Mercredi, avril 10, 2024
Breast cancer, FDA, Patient, Cancer, Daiichi Sankyo, Lung cancer, HER2, Food, ROG, Marie Cassidy, ADC, Food and Drug Administration, AstraZeneca, CE marking, Medical imaging

ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.

Key Points: 
  • ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.
  • To determine a patient's HER2 status, pathologists evaluate, or score, the level of HER2 protein expressed in breast cancer tissue samples.
  • However, half of all patients with metastatic breast cancer express low levels of HER2 which historically classified them as HER2-negative.
  • Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases diagnosed worldwide each year.